0001193125-26-197192.txt : 20260430 0001193125-26-197192.hdr.sgml : 20260430 20260430160630 ACCESSION NUMBER: 0001193125-26-197192 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20260430 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20260430 DATE AS OF CHANGE: 20260430 FILER: COMPANY DATA: COMPANY CONFORMED NAME: RESMED INC CENTRAL INDEX KEY: 0000943819 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 980152841 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-15317 FILM NUMBER: 26925106 BUSINESS ADDRESS: STREET 1: 9001 SPECTRUM CENTER BLVD. CITY: SAN DIEGO STATE: CA ZIP: 92123 BUSINESS PHONE: 8587462400 MAIL ADDRESS: STREET 1: 9001 SPECTRUM CENTER BLVD. CITY: SAN DIEGO STATE: CA ZIP: 92123 8-K 1 d146862d8k.htm 8-K 8-K
RESMED INC US false 0000943819 0000943819 2026-04-30 2026-04-30
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Under Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

April 30, 2026

 

 

ResMed Inc.

(Exact Name of Registrant as Specified in Charter)

 

 

 

Delaware   001-15317   98-0152841

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

9001 Spectrum Center Blvd.

San Diego, California 92123

(Address of Principal Executive Offices)

(858) 836-5000

(Registrant’s telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.004 par value   RMD   NYSE

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ☐

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 

Item 2.02. Results of Operations and Financial Condition.

On April 30, 2026, we issued the press release furnished as Exhibit 99.1. The press release describes the results of our operations for the quarter ended March 31, 2026.

The information furnished in this Current Report on Form 8-K under Item 2.02 and the attached exhibit shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 8.01. Other Events.

On April 30, 2026, we announced that our board of directors declared a quarterly cash dividend of US $0.60 per share. The dividend will have a record date of May 14, 2026, payable on June 18, 2026. The dividend will be paid in U.S. currency to holders of Resmed’s common stock trading on the New York Stock Exchange. Holders of CHESS Depositary Interests (“CDIs”) trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares. The ex-dividend date will be May 13, 2026, for common stockholders and for CDI holders. Resmed has received a waiver from the ASX’s settlement operating rules, which will allow Resmed to defer processing conversions between its common stock and CDI registers from May 13, 2026, through May 14, 2026, inclusive.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

 

Exhibits:

   

Description of Document

99.1    Press Release dated April 30, 2026, regarding results of operations
104    Cover Page Interactive Data File (embedded within the Inline XBRL, document)

 

-2-

SIGNATURES

We have authorized the person whose signature appears below to sign this report on our behalf, in accordance with the Securities Exchange Act of 1934.

 

Date: April 30, 2026

     ResMed Inc.
   

(registrant)

       

By:

  

/s/ Brett Sandercock

       

Name:

  

Brett Sandercock

       

Its:

  

Chief Financial Officer

 

-3-

EX-99.1 2 d146862dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

 

For investors    For media
+1 858-221-3304    +1 619-510-1281
investorrelations@resmed.com    news@resmed.com

Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2026

 

  •  

Revenue increased by 11% to $1.4 billion; up 8% on a constant currency basis

 

  •  

GAAP gross margin up 290 bps to 62.2%; non-GAAP gross margin up 290 bps to 62.8%

 

  •  

GAAP income from operations increased 17%; non-GAAP income from operations up 18%

 

  •  

GAAP diluted earnings per share of $2.74; non-GAAP diluted earnings per share of $2.86

 

  •  

Operating cash flow of $554 million; $262 million returned to shareholders through share repurchases and dividends

Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com

SAN DIEGO, April 30, 2026 – Resmed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended March 31, 2026.

“Our third quarter results reflect the continued strength of our global business, driven by ongoing demand for our market-leading products and disciplined execution of our strategy,” said Resmed’s Chairman and CEO, Mick Farrell.

“Year-over-year, we delivered 11% reported revenue growth, 290 basis points of non-GAAP gross margin expansion, and 21% increase in earnings per share. These results highlight the momentum behind our strategy, and the continued progress we are making in shaping the future of sleep health, breathing health, and healthcare in the home.

As we advance through the remainder of our fiscal year 2026, we remain focused on expanding access to care globally, scaling our digital health capabilities, and delivering further strong, profitable growth.”

RMD Third Quarter 2026 Earnings Press Release – April 30, 2026

Page 2 of 10

 

 

 

Financial Results and Operating Metrics

Unaudited; $ in millions, except for per share amounts

 

     Three Months Ended  
     March 31,
2026		     March 31,
2025		     % Change     Constant
Currency  (A)		  

Revenue

    $ 1,431.4     $ 1,291.7       11 %      8 % 

Gross margin

      62.2 %      59.3 %      5    

Non-GAAP gross margin (B)

      62.8 %      59.9 %      5    

Selling, general, and administrative expenses

      285.7       245.3       16       11  

Non-GAAP selling, general, and administrative expenses(B)

      279.8       245.3       14       9  

Research and development expenses

      94.3       83.9       12       8  

Income from operations

      499.8       426.3       17    

Non-GAAP income from operations (B)

      524.8       444.6       18    

Net income

      398.7       365.0       9    

Non-GAAP net income (B)

      417.2       348.5       20    

Diluted earnings per share

    $ 2.74     $ 2.48       10    

Non-GAAP diluted earnings per share (B)

    $ 2.86     $ 2.37       21    

 

     Nine Months Ended  
     March 31,
2026		     March 31,
2025		     % Change     Constant
Currency  (A)		  

Revenue

    $ 4,189.8     $ 3,798.3       10 %      8 % 

Gross margin

      61.8 %      58.8 %      5    

Non-GAAP gross margin (B)

      62.4 %      59.4 %      5    

Selling, general, and administrative expenses

      823.2       725.9       13       10  

Non-GAAP selling, general, and administrative expenses(B)

      817.4       725.9       13       9  

Research and development expenses

      272.6       244.8       11       9  

Income from operations

      1,438.0       1,230.8       17    

Non-GAAP income from operations (B)

      1,524.1       1,286.9       18    

Net income

      1,139.9       1,021.0       12    

Non-GAAP net income (B)

      1,203.5       1,032.2       17    

Diluted earnings per share

    $ 7.79     $ 6.93       12    

Non-GAAP diluted earnings per share (B)

    $ 8.22     $ 7.00       17    

 

(A)

In order to provide a framework for assessing how our underlying businesses performed, excluding the effect of foreign currency fluctuations, we provide certain financial information on a “constant currency” basis, which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.

(B)

See the reconciliation of non-GAAP financial measures in the table at the end of the press release.

Discussion of Third Quarter Results

All comparisons are to the prior year period unless otherwise noted

 

  •  

Revenue grew by 8 percent on a constant currency basis, driven by increased demand for our portfolio of sleep devices, masks and accessories.

 

  •  

Revenue in the U.S., Canada, and Latin America, excluding Residential Care Software, grew by 9 percent.

 

  •  

Revenue in Europe, Asia, and other markets, excluding Residential Care Software, grew by 7 percent on a constant currency basis.

 

  •  

Residential Care Software revenue increased by 4 percent on a constant currency basis.

RMD Third Quarter 2026 Earnings Press Release – April 30, 2026

Page 3 of 10

 

 

 

  •  

Gross margin increased by 290 basis points primarily driven by component cost improvements and manufacturing and logistics efficiencies, as well as a small positive impact from product mix and foreign currency movements. Non-GAAP gross margin increased by 290 basis points due to the same factors.

 

  •  

Selling, general, and administrative expenses increased by 11 percent on a constant currency basis. The increase in SG&A expenses was mainly due to additional expenses associated with our VirtuOx acquisition, employee costs as well as marketing and technology investments. Additionally, we recorded acquisition and portfolio review related expenses of $5.9 million reflecting costs associated with the evaluation of strategic transactions, including legal and professional fees for diligence and related consultations. SG&A expenses, excluding acquisition and portfolio review related expenses, were 19.5 percent of revenue in the quarter, compared with 19.0 percent in the same period of the prior year.

 

  •  

Income from operations increased by 17 percent and non-GAAP income from operations increased by 18 percent.

 

  •  

Net income for the quarter was $399 million and diluted earnings per share was $2.74. Non-GAAP net income increased by 20 percent to $417 million, and non-GAAP diluted earnings per share increased by 21 percent to $2.86, predominantly attributable to strong sales growth and gross margin improvement.

 

  •  

Operating cash flow for the quarter was $554 million, compared to net income in the current quarter of $399 million and non-GAAP net income of $417 million.

 

  •  

During the quarter, we paid $87 million in dividends to shareholders and repurchased 673,000 shares for consideration of $175 million as part of our ongoing capital management.

Other Business and Operational Highlights

 

  •  

Unveiled findings from sixth annual Global Sleep Survey, drawing insights from 30,000 people across 13 countries; as sleep awareness grows, so does the opportunity to turn intent into action.

 

  •  

Announced expansion of U.S. operations with new distribution center in Greenwood, Indiana, scheduled to begin operations in 2027 and expand Resmed’s U.S. presence while strengthening the company’s distribution capacity to better serve patients and providers across North America.

 

  •  

Launched the AirTouch F30i Comfort full face mask in the U.S. following its introduction in Australia and Canada, and building on the launch of the AirTouch F30i Clear in the U.S.

RMD Third Quarter 2026 Earnings Press Release – April 30, 2026

Page 4 of 10

 

Dividend program

The Resmed board of directors today declared a quarterly cash dividend of $0.60 per share. The dividend will have a record date of May 14, 2026, payable on June 18, 2026. The dividend will be paid in U.S. currency to holders of Resmed’s common stock trading on the New York Stock Exchange. Holders of CHESS Depositary Interests (“CDIs”) trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares. The ex-dividend date will be May 13, 2026, for common stockholders and for CDI holders. Resmed has received a waiver from the ASX’s settlement operating rules, which will allow Resmed to defer processing conversions between its common stock and CDI registers from May 13, 2026, through May 14, 2026, inclusive.

Webcast details

Resmed will discuss its third quarter fiscal year 2026 results on its webcast at 1:30 p.m. U.S. Pacific Time today. The live webcast of the call can be accessed on Resmed’s Investor Relations website at investor.resmed.com. Please go to this section of the website and click on the icon for the “Q3 2026 Earnings Webcast” to register and listen to the live webcast. A replay of the earnings webcast will be accessible on the website and available approximately two hours after the live webcast. In addition, a telephone replay of the conference call will be available approximately three hours after the webcast by dialing +1 877-660-6853 (U.S.) or +1 201-612-7415 (outside U.S.) and entering the passcode 13759381. The telephone replay will be available until May 14, 2026.

About Resmed

Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we’re redefining sleep health at Resmed.com and follow @Resmed.

Safe harbor statement

Statements contained in this release that are not historical facts are “forward-looking” statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements – including statements regarding Resmed’s projections of future revenue or earnings, expenses, new product development, new product launches, new markets for its products, the integration of acquisitions, our supply chain, domestic and international regulatory developments, litigation, tax outlook, and the expected impact of macroeconomic conditions of our business – are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Additional risks and uncertainties are discussed in Resmed’s periodic reports on file with the U.S. Securities & Exchange Commission. Resmed does not undertake to update its forward-looking statements.

 

– More –

RMD Third Quarter 2026 Earnings Press Release – April 30, 2026

Page 5 of 10

 

RESMED INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Operations

(Unaudited; $ in thousands, except for per share amounts)

 

     Three Months Ended     Nine Months Ended  
     March 31,
2026		     March 31,
2025		     March 31,
2026		     March 31,
2025		  

Net revenue

    $ 1,431,406     $ 1,291,736     $ 4,189,796     $ 3,798,334  

Cost of sales

      532,577       517,883       1,575,796       1,540,684  

Amortization of acquired intangibles (1)

      7,850       7,444       23,480       22,748  
  

 

 

    

 

 

    

 

 

    

 

 

  

Total cost of sales

    $ 540,427     $ 525,327     $ 1,599,276     $ 1,563,432  
  

 

 

    

 

 

    

 

 

    

 

 

  

Gross profit

    $ 890,979     $ 766,409     $ 2,590,520     $ 2,234,902  

Selling, general, and administrative

      279,797       245,302       817,387       725,894  

Acquisition and portfolio review related expenses (1)

      5,858       —        5,858       —   
  

 

 

    

 

 

    

 

 

    

 

 

  

Total selling, general, and administrative

      285,655       245,302       823,245       725,894  
  

 

 

    

 

 

    

 

 

    

 

 

  

Research and development

      94,267       83,944       272,560       244,840  

Amortization of acquired intangibles (1)

      11,247       10,895       34,967       33,345  

Restructuring expenses (1)

      —        —        21,745       —   
  

 

 

    

 

 

    

 

 

    

 

 

  

Total operating expenses

    $ 391,169     $ 340,141     $ 1,152,517     $ 1,004,079  
  

 

 

    

 

 

    

 

 

    

 

 

  

Income from operations

    $ 499,810     $ 426,268     $ 1,438,003     $ 1,230,823  

Other income (expenses), net:

         

Interest (expense) income, net

    $ 12,287     $ 793     $ 29,029     $ (1,643 ) 

Gain (loss) attributable to equity method investments

      1,718       335       4,722       2,375  

Gain (loss) on equity investments

      (10,130 )      (5,647 )      (16,014 )      (7,765 ) 

Other, net

      (1,373 )      (4,056 )      (10,488 )      (4,277 ) 
  

 

 

    

 

 

    

 

 

    

 

 

  

Total other income (expenses), net

      2,502       (8,575 )      7,249       (11,310 ) 
  

 

 

    

 

 

    

 

 

    

 

 

  

Income before income taxes

    $ 502,312     $ 417,693     $ 1,445,252     $ 1,219,513  

Income taxes

      103,580       52,652       305,391       198,495  
  

 

 

    

 

 

    

 

 

    

 

 

  

Net income

    $ 398,732     $ 365,041     $ 1,139,861     $ 1,021,018  
  

 

 

    

 

 

    

 

 

    

 

 

  

Basic earnings per share

    $ 2.74     $ 2.49     $ 7.82     $ 6.96  

Diluted earnings per share

    $ 2.74     $ 2.48     $ 7.79     $ 6.93  

Non-GAAP diluted earnings per share (1)

    $ 2.86     $ 2.37     $ 8.22     $ 7.00  

Basic shares outstanding

      145,340       146,719       145,794       146,797  

Diluted shares outstanding

      145,723       147,220       146,369       147,432  

 

(1)

See the reconciliation of non-GAAP financial measures in the table at the end of the press release.

 

– More –

RMD Third Quarter 2026 Earnings Press Release – April 30, 2026

Page 6 of 10

 

RESMED INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(Unaudited; $ in thousands)

 

     March 31,
2026		     June 30,
2025		  

Assets

     

Current assets:

     

Cash and cash equivalents

    $ 1,660,513     $ 1,209,450  

Accounts receivable, net

      998,837       939,492  

Inventories

      911,876       927,711  

Prepayments and other current assets

      492,836       428,952  
  

 

 

    

 

 

  

Total current assets

    $ 4,064,062     $ 3,505,605  

Non-current assets:

     

Property, plant, and equipment, net

    $ 566,972     $ 550,790  

Operating lease right-of-use assets

      161,602       167,497  

Goodwill and other intangibles, net

      3,468,321       3,511,541  

Deferred income taxes and other non-current assets

      523,328       438,958  
  

 

 

    

 

 

  

Total non-current assets

    $ 4,720,223     $ 4,668,786  
  

 

 

    

 

 

  

Total assets

    $ 8,784,285     $ 8,174,391  
  

 

 

    

 

 

  

Liabilities and Stockholders’ Equity

     

Current liabilities:

     

Accounts payable

    $ 273,301     $ 278,157  

Accrued expenses

      446,149       402,253  

Operating lease liabilities, current

      29,233       30,506  

Deferred revenue

      179,277       166,030  

Income taxes payable

      163,322       132,274  

Short-term debt

      259,928       9,900  
  

 

 

    

 

 

  

Total current liabilities

    $ 1,351,210     $ 1,019,120  

Non-current liabilities:

     

Deferred revenue

    $ 163,148     $ 156,803  

Deferred income taxes

      77,929       77,682  

Operating lease liabilities, non-current

      149,840       153,015  

Other long-term liabilities

      146,079       141,520  

Long-term debt

      404,168       658,392  
  

 

 

    

 

 

  

Total non-current liabilities

    $ 941,164     $ 1,187,412  
  

 

 

    

 

 

  

Total liabilities

    $ 2,292,374     $ 2,206,532  
  

 

 

    

 

 

  

Stockholders’ equity

     

Common stock

    $ 763     $ 761  

Additional paid-in capital

      2,134,231       2,033,599  

Retained earnings

      6,958,779       6,081,490  

Treasury stock

      (2,576,957 )      (2,073,292 ) 

Accumulated other comprehensive income

      (24,905 )      (74,699 ) 
  

 

 

    

 

 

  

Total stockholders’ equity

    $ 6,491,911     $ 5,967,859  
  

 

 

    

 

 

  

Total liabilities and stockholders’ equity

    $ 8,784,285     $ 8,174,391  
  

 

 

    

 

 

  

 

– More –

RMD Third Quarter 2026 Earnings Press Release – April 30, 2026

Page 7 of 10

 

RESMED INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows

(Unaudited; $ in thousands)

 

     Three Months Ended     Nine Months Ended  
     March 31,
2026		     March 31,
2025		     March 31,
2026		     March 31,
2025		  

Cash flows from operating activities:

         

Net income

    $ 398,732     $ 365,041     $ 1,139,861     $ 1,021,018  

Adjustment to reconcile net income to cash provided by operating activities:

         

Depreciation and amortization

      58,981       43,675       156,564       134,845  

Amortization of right-of-use assets

      10,051       8,235       32,467       26,678  

Stock-based compensation costs

      26,792       24,120       76,890       66,910  

(Gain) loss attributable to equity method investments, net of dividends received

      (1,718 )      (335 )      (4,722 )      (2,375 ) 

(Gain) loss on equity investments

      10,130       5,647       16,014       7,765  

Changes in operating assets and liabilities:

         

Accounts receivable, net

      (16,857 )      (40,033 )      (59,569 )      (71,469 ) 

Inventories, net

      12,480       29,864       23,946       (48,032 ) 

Prepaid expenses, net deferred income taxes and other current assets

      (48,335 )      79,357       (152,410 )      35,612  

Accounts payable, accrued expenses, income taxes payable and other

      103,876       63,091       122,157       41,870  
  

 

 

    

 

 

    

 

 

    

 

 

  

Net cash provided by (used in) operating activities

    $ 554,132     $ 578,662     $ 1,351,198     $ 1,212,822  

Cash flows from investing activities:

         

Purchases of property, plant, and equipment

      (33,654 )      (20,796 )      (105,158 )      (59,280 ) 

Patent registration and acquisition costs

      (5,935 )      (2,992 )      (13,286 )      (7,584 ) 

Purchases of intangible assets

      —         —         (1,479 )      —    

Business acquisitions, net of cash acquired

      (24,883 )      —         (25,405 )      (670 ) 

Purchases of investments

      (20,132 )      (2,053 )      (26,536 )      (4,403 ) 

Proceeds from exits of investments

      2,502       —         2,752       4,378  

Proceeds (payments) on maturity of foreign currency contracts

      24,074       (5,945 )      7,564       1,227  
  

 

 

    

 

 

    

 

 

    

 

 

  

Net cash provided by (used in) investing activities

    $ (58,028 )    $ (31,786 )    $ (161,548 )    $ (66,332 ) 

Cash flows from financing activities:

         

Proceeds from issuance of common stock, net

      7,427       9,022       45,189       44,283  

Purchases of treasury stock

      (175,013 )      (75,026 )      (500,037 )      (200,017 ) 

Taxes paid related to net share settlement of equity awards

      (418 )      (364 )      (21,445 )      (17,487 ) 

Payments of business combination contingent consideration

      —         —         —         (855 ) 

Repayment of borrowings

      —         —         (5,000 )      (35,000 ) 

Dividends paid

      (87,238 )      (77,704 )      (262,572 )      (233,290 ) 
  

 

 

    

 

 

    

 

 

    

 

 

  

Net cash provided by (used in) financing activities

    $ (255,242 )    $ (144,072 )    $ (743,865 )    $ (442,366 ) 
  

 

 

    

 

 

    

 

 

    

 

 

  

Effect of exchange rate changes on cash

    $ 2,582     $ 7,963     $ 5,278     $ (9,774 ) 
  

 

 

    

 

 

    

 

 

    

 

 

  

Net increase (decrease) in cash and cash equivalents

      243,444       410,767       451,063       694,350  

Cash and cash equivalents at beginning of period

      1,417,069       521,944       1,209,450       238,361  
  

 

 

    

 

 

    

 

 

    

 

 

  

Cash and cash equivalents at end of period

    $ 1,660,513     $ 932,711     $ 1,660,513     $ 932,711  
  

 

 

    

 

 

    

 

 

    

 

 

  

 

 

– More –

RMD Third Quarter 2026 Earnings Press Release – April 30, 2026

Page 8 of 10

 

RESMED INC. AND SUBSIDIARIES

Reconciliation of Non-GAAP Financial Measures

(Unaudited; $ in thousands, except for per share amounts)

The measures “non-GAAP gross profit” and “non-GAAP gross margin” exclude amortization expense from acquired intangibles and are reconciled below:

 

     Three Months Ended     Nine Months Ended  
     March 31,
2026		     March 31,
2025		     March 31,
2026		     March 31,
2025		  

Revenue

    $ 1,431,406     $ 1,291,736     $ 4,189,796     $ 3,798,334  

GAAP cost of sales

    $ 540,427     $ 525,327     $ 1,599,276     $ 1,563,432  

Less: Amortization of acquired intangibles (A)

      (7,850 )      (7,444 )      (23,480 )      (22,748 ) 
  

 

 

    

 

 

    

 

 

    

 

 

  

Non-GAAP cost of sales

    $ 532,577     $ 517,883     $ 1,575,796     $ 1,540,684  

GAAP gross profit

    $ 890,979     $ 766,409     $ 2,590,520     $ 2,234,902  

GAAP gross margin

      62.2 %      59.3 %      61.8 %      58.8 % 

Non-GAAP gross profit

    $ 898,829     $ 773,853     $ 2,614,000     $ 2,257,650  

Non-GAAP gross margin

      62.8 %      59.9 %      62.4 %      59.4 % 

The measures “non-GAAP selling, general, and administrative expenses” and “non-GAAP selling, general, and administrative expenses as a percentage of revenues” exclude acquisition and portfolio review related expenses and are reconciled below:

 

     Three Months Ended     Nine Months Ended  
     March 31,
2026		     March 31,
2025		     March 31,
2026		     March 31,
2025		  

Revenue

    $ 1,431,406     $ 1,291,736     $ 4,189,796     $ 3,798,334  

GAAP selling, general, and administrative

      285,655       245,302       823,245       725,894  

Less: Acquisition and portfolio review related expenses (A)

      (5,858 )      —        (5,858 )      —   
  

 

 

    

 

 

    

 

 

    

 

 

  

Non-GAAP selling, general, and administrative

      279,797       245,302       817,387       725,894  
  

 

 

    

 

 

    

 

 

    

 

 

  

As a percentage of revenue:

         

GAAP selling, general, and administrative expenses

      20.0 %      19.0 %      19.6 %      19.1 % 

Non-GAAP selling, general, and administrative expenses

      19.5 %      19.0 %      19.5 %      19.1 % 

The measure “non-GAAP income from operations” is reconciled with GAAP income from operations below:

 

     Three Months Ended      Nine Months Ended  
     March 31,
2026		      March 31,
2025		      March 31,
2026		      March 31,
2025		  

GAAP income from operations

    $ 499,810      $ 426,268      $ 1,438,003      $ 1,230,823  

Amortization of acquired intangibles—cost of sales (A)

      7,850        7,444        23,480        22,748  

Amortization of acquired intangibles—operating expenses (A)

      11,247        10,895        34,967        33,345  

Restructuring (A)

      —         —         21,745        —  

Acquisition and portfolio review related expenses (A)

      5,858        —         5,858        —  
  

 

 

     

 

 

     

 

 

     

 

 

  

Non-GAAP income from operations

    $ 524,765      $ 444,607      $ 1,524,053      $ 1,286,916  
  

 

 

     

 

 

     

 

 

     

 

 

  

 

– More –

RMD Third Quarter 2026 Earnings Press Release – April 30, 2026

Page 9 of 10

 

RESMED INC. AND SUBSIDIARIES

Reconciliation of Non-GAAP Financial Measures

(Unaudited; $ in thousands, except for per share amounts)

The measures “non-GAAP net income” and “non-GAAP diluted earnings per share” are reconciled with GAAP net income and GAAP diluted earnings per share in the table below:

 

     Three Months Ended     Nine Months Ended  
     March 31,
2026		     March 31,
2025		     March 31,
2026		     March 31,
2025		  

GAAP net income

    $ 398,732     $ 365,041     $ 1,139,861     $ 1,021,018  

Amortization of acquired intangibles—cost of sales (A)

      7,850       7,444       23,480       22,748  

Amortization of acquired intangibles—operating expenses (A)

      11,247       10,895       34,967       33,345  

Restructuring expenses (A)

      —         —         21,745       —    

Acquisition and portfolio review related expenses (A)

      5,858       —         5,858       —    

Income tax effect of interest and penalties on income tax refunds (A)

      —         (29,976 )      —         (29,976 ) 

Income tax effect on non-GAAP adjustments (A)

      (6,519 )      (4,871 )      (22,394 )      (14,904 ) 
  

 

 

    

 

 

    

 

 

    

 

 

  

Non-GAAP net income (A)

    $ 417,168     $ 348,533     $ 1,203,517     $ 1,032,231  
  

 

 

    

 

 

    

 

 

    

 

 

  

GAAP diluted shares outstanding

      145,723       147,220       146,369       147,432  

GAAP diluted earnings per share

    $ 2.74     $ 2.48     $ 7.79     $ 6.93  

Non-GAAP diluted earnings per share (A)

    $ 2.86     $ 2.37     $ 8.22     $ 7.00  

 

(A)

Resmed adjusts for the impact of the amortization of acquired intangibles, restructuring expenses, and acquisition and portfolio review related expenses from their evaluation of ongoing operations, and believes that investors benefit from adjusting these items to facilitate a more meaningful evaluation of current operating performance.

Resmed believes that non-GAAP diluted earnings per share is an additional measure of performance that investors can use to compare operating results between reporting periods. Resmed uses non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. Resmed believes this information provides investors better insight when evaluating Resmed’s performance from core operations and provides consistent financial reporting. The use of non-GAAP measures is intended to supplement, and not to replace, the presentation of net income and other GAAP measures. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under GAAP.

 

– More –

RMD Third Quarter 2026 Earnings Press Release – April 30, 2026

Page 10 of 10

 

RESMED INC. AND SUBSIDIARIES

Revenue by Product and Region

(Unaudited; $ in millions, except for per share amounts)

 

     Three Months Ended  
     March 31,
2026		      (A)       March 31,
2025		      (A)       % Change     Constant
Currency  (B)		  

U.S., Canada, and Latin America

                 

Devices

    $ 447.5         $ 422.7           6 %   

Masks and other

      371.2           326.7           14    
  

 

 

        

 

 

        

 

 

    

 

 

  

Total U.S., Canada and Latin America

    $ 818.7         $ 749.3           9    

Combined Europe, Asia, and other markets

                 

Devices

    $ 288.2         $ 253.5           14 %      6 % 

Masks and other

      153.6           127.7           20       10  
  

 

 

        

 

 

        

 

 

    

 

 

  

Total Combined Europe, Asia and other markets

    $ 441.8         $ 381.3           16       7  

Global revenue

                 

Total Devices

    $ 735.7         $ 676.2           9 %      6 % 

Total Masks and other

      524.8           454.4           15       12  
  

 

 

        

 

 

        

 

 

    

 

 

  

Total Sleep and Breathing Health

    $ 1,260.5         $ 1,130.6           11       8  

Residential Care Software

      170.9           161.2           6       4  
  

 

 

        

 

 

        

 

 

    

 

 

  

Total

    $ 1,431.4         $ 1,291.7           11       8  
  

 

 

        

 

 

        

 

 

    

 

 

  

 

     Nine Months Ended  
     March 31,
2026		      (A)       March 31,
2025		      (A)       %
Change		     Constant
Currency  (B)		  

U.S., Canada, and Latin America

                 

Devices

    $ 1,309.0         $ 1,221.6           7 %   

Masks and other

      1,119.5           983.9           14    
  

 

 

        

 

 

        

 

 

    

 

 

  

Total U.S., Canada and Latin America

    $ 2,428.5         $ 2,205.6           10    

Combined Europe, Asia, and other markets

                 

Devices

    $ 833.3         $ 749.6           11 %      6 % 

Masks and other

      424.2           368.7           15       7  
  

 

 

        

 

 

        

 

 

    

 

 

  

Total Combined Europe, Asia and other markets

    $ 1,257.4         $ 1,118.3           12       6  

Global revenue

                 

Total Devices

    $ 2,142.3         $ 1,971.3           9 %      7 % 

Total Masks and other

      1,543.6           1,352.6           14       12  
  

 

 

        

 

 

        

 

 

    

 

 

  

Total Sleep and Breathing Health

    $ 3,685.9         $ 3,323.9           11       9  

Residential Care Software

      503.9           474.4           6       4  
  

 

 

        

 

 

        

 

 

    

 

 

  

Total

    $ 4,189.8         $ 3,798.3           10       8  
  

 

 

        

 

 

        

 

 

    

 

 

  

 

(A)

Totals and subtotals may not add due to rounding.

(B)

In order to provide a framework for assessing how our underlying businesses performed excluding the effect of foreign currency fluctuations, we provide certain financial information on a “constant currency basis,” which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.

 

– End –

EX-101.SCH 3 rmd-20260430.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 rmd-20260430_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Entity Address, Country Entity Address, Country Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 rmd-20260430_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g146862dsp004.jpg GRAPHIC begin 644 g146862dsp004.jpg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htm IDEA: XBRL DOCUMENT v3.26.1
Document and Entity Information
Apr. 30, 2026
Cover [Abstract]  
Entity Registrant Name RESMED INC
Entity Address, Country US
Amendment Flag false
Entity Central Index Key 0000943819
Document Type 8-K
Document Period End Date Apr. 30, 2026
Entity Incorporation State Country Code DE
Entity File Number 001-15317
Entity Tax Identification Number 98-0152841
Entity Address, Address Line One 9001 Spectrum Center Blvd.
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92123
City Area Code (858)
Local Phone Number 836-5000
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.004 par value
Trading Symbol RMD
Security Exchange Name NYSE
Entity Emerging Growth Company false
XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.26.1 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://investor.resmed.com//20260430/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d146862d8k.htm rmd-20260430.xsd rmd-20260430_lab.xml rmd-20260430_pre.xml http://xbrl.sec.gov/dei/2025 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d146862d8k.htm": { "nsprefix": "rmd", "nsuri": "http://investor.resmed.com/20260430", "dts": { "inline": { "local": [ "d146862d8k.htm" ] }, "schema": { "local": [ "rmd-20260430.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd", "https://xbrl.sec.gov/country/2025/country-2025.xsd", "https://xbrl.sec.gov/dei/2025/dei-2025.xsd", "https://xbrl.sec.gov/naics/2025/naics-2025.xsd", "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" ] }, "labelLink": { "local": [ "rmd-20260430_lab.xml" ] }, "presentationLink": { "local": [ "rmd-20260430_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 4, "http://xbrl.sec.gov/dei/2025": 4 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2025": 23 }, "report": { "R1": { "role": "http://investor.resmed.com//20260430/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2026-04-30_to_2026-04-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d146862d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2026-04-30_to_2026-04-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d146862d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentFlag", "presentation": [ "http://investor.resmed.com//20260430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CityAreaCode", "presentation": [ "http://investor.resmed.com//20260430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentPeriodEndDate", "presentation": [ "http://investor.resmed.com//20260430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentType", "presentation": [ "http://investor.resmed.com//20260430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine1", "presentation": [ "http://investor.resmed.com//20260430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCityOrTown", "presentation": [ "http://investor.resmed.com//20260430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCountry", "presentation": [ "http://investor.resmed.com//20260430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "terseLabel": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://investor.resmed.com//20260430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://investor.resmed.com//20260430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCentralIndexKey", "presentation": [ "http://investor.resmed.com//20260430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://investor.resmed.com//20260430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFileNumber", "presentation": [ "http://investor.resmed.com//20260430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://investor.resmed.com//20260430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityRegistrantName", "presentation": [ "http://investor.resmed.com//20260430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://investor.resmed.com//20260430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "LocalPhoneNumber", "presentation": [ "http://investor.resmed.com//20260430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://investor.resmed.com//20260430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "PreCommencementTenderOffer", "presentation": [ "http://investor.resmed.com//20260430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Security12bTitle", "presentation": [ "http://investor.resmed.com//20260430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SecurityExchangeName", "presentation": [ "http://investor.resmed.com//20260430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SolicitingMaterial", "presentation": [ "http://investor.resmed.com//20260430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "TradingSymbol", "presentation": [ "http://investor.resmed.com//20260430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "WrittenCommunications", "presentation": [ "http://investor.resmed.com//20260430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 16 0001193125-26-197192-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-26-197192-xbrl.zip M4$L#!!0 ( ,^ GER'4:.CQ1 $%I . 9#$T-C@V,F0X:RYH=&WM M/6MSXCBVW_,K5,R=G:0J!AM( B3-5IK0T^QT'@7IFMG[I4O8(FC;V%Y)#G!_ M_3U'?F#>A #IGDJJ.L'H=73>#\E]]<_1P"7/3$CN>Q]^L_+F;X1YMN]P[^G# M;]>=1JOUVS_K1U=]!=V@JR=K#N,?U1V\[YX*B0M4]T]W_/"0=IY.!SF]?0XP%&B@",*T,F 7DQP M.QDW#[;*_/K:_3+JKQ?TG70M*4$_V?#&@"A@& M9SHSS*)1/,],8@!#3$V4,,BZ>2I&R4IQ"8OS55N=P2*V.C.,&7<^+T2-25_80'&:XO;-;0CU68]Z!4*3=EO*".&639*YC?E9YYR M]7:S<]N\(:V[QE5A"IK-H+MV'!!%V?!#3XGQM_4+SL$_/<.+X?_:60?W9,'K M ?,<^*<^N?3II2OI_?/1,TA9.5?O45>RK3#6@/4%=5N>PT9_L/$\0N8ZO! C M)OQ4RZ6*59V'KS##?(+UF !+PR0\H^*M2:T>8:U]ZG6]$EJ2#SG)!X&;?M<7 MN$G0^$:BU?,CZ22M5-C"1_%:OT8AWNS4!O6S]$,1/6KE5HNQJXFU 7:384S3 M*GWD#G[1XTP0C4&V4/4V6G],TV=V,$*]Z'=RG()U$ M^4$M\]CUE?('^INN+P#XY!LK&!'IN]PAOYCZ)U?_QR_6N7FY8&_9Q4KK%RN^ M?+$@62HS<1FF(?/;(#T@D2'Y_[&:54F?>W3 W7'MNMVZ_G*IOQE&\'9]U[E< M0)RO=ZU'L .=Q^O')JC48 D0YEZ!Z#0;7]NMQU:S0Z[O;DCSK\;GZ[O?FZ1Q M?WO;ZG1:]W>O@JRX/61_7G<^M^Y^?[R_.R4W^4:>%,VSX\>T0782,Z[>%BW!QEHM3WB.HS MA"@47'$F27-D]ZGWQ,BUK0@T6]52>3ET^R4:^BX(0YL%OE#D.'EF%'P7)A5A MS]"3"-W,G)/:6Z%QK;IYT'Y7,W+'7JQWHA >=8^J.3#! (;W'3H> R*8E]5+ MY[GZ=2"X2TKF*<$IYE74NV[:AVXJEK?GGFES1C"S8_"1$05RM749@WJ;R5OF MD)9GYV,#1%XE!^;V.SENCBBH#80KDML$4D(EZ03,QBC((=PCC3Y$,4S,*KYW M?ES.CZ_ S=&5HEV7$9NY+CI*F'?.@6+!YX Z3O(Z:@5Y\1LC:578[":JU[Z&C4=E^[B/U_ 9[:V5]$5$U0T6#D=!B@1#DA#0T$^NL].?DV8>K 9C., M-.#CO7CTA]XK\&'EZAVPHC>AKP/ @C! M ^J2YHC9H>+/C-SW0/Z97)'D>R,Q1SZ^!I?GE>0H PHJ9Y63>:[8VD_\XH-- M>>C[WJN=ZPJFZDOGQAE$Z)OEZP_&-I/TR#]^J12MBTM)%'-9@-LFGM[W*0%V M9\#,JPS^SO.GE. ]"8@>#H7'?] M$>DRUQ\2'F76/X&&72\'NI84I>YZW$5B(1[@=P&^R,F(D_IBDGT+==V!>N.DK>>[ "2.0VW/T2.5L]GS"5[. MM\TWO2Z?9&7*^),LTB3#-)^_FLEO;13AY19E?\J_7J[V;)$G%\7)\5X>^8!) M&I.T/J+="T_TIN (Z8V00>K&;*%]MR+N^[W8IT%@!1V:UX3G2J7I1+E]N MFY99B(@,VY!I3B$[E+D85X"<++)($ H9(IN#H+1#8+MR\2QF^9GB%M:TCJT+ MTOC4)L62F8>.Z]WQ=SDXA!QTP"K80"7OZ184*6A3=W]"ULQ;*9CV8\R?A4[U+UYE+U(!A:%CPAJ4^] MH$,A(![9PJ/>6+HJ/[-TK65UP*AA9U":B- ZF[2!1#I&\;A[LEN9C.9\E\H? M62I;4H9,'$0VJ^^RN95LEIA1/K9W*YOQG!O+YL'R11F'.8HAF8 H-(NU^ 1; M)/T6:I@DL 0T+(\CW\\M_'3G%N;KFQOD=); /2<(KRH5[:Y&\XCWQ*)SA7:? MV"Z5UL:TQ]6-4T!X%10%[H\)99SR IF.YFS+E3TZ*Y$"=9E 6FYRWJME[ M!"09X)C8AFG3];;'I9;F%R*C-K:*72WOVU<4JN!DHOL&B.@HW_Y^2O['!(8J MDX *\DS=<,&)I\._.C[2ZA;.**;7-/=LZ#1B&; M*X)6BR"*_^XT%V)@KV[;(G>XY3GHTC+2'1-;5R-@ZN\@G$P?[YDI 7!)P"<% MMQA7?R)/PA^J/GK& 98%J"0.ZW$O.IP;)5'-,S)_/6!R*Z!$CI&@%Y[<631ANZU\6ND>:B-KN2L'[2!#ITM>?FSX"9)SN(Z*(R=S/&[N\: MN8T(MWL+YJJE]<'<[@O.BSBQN9BK#K5\J[>"M;&"NE!.^%R5K ]2P%P(;4 * M/%\'.J%DNA>L&M?B\)4*7)?9HKNT2"Z]ECO&Q8<LC+)*QS2-LK(2\1+^3=EE]3TU:Y,+MDOK MR'^KN[I39>6CHX7<;+'!'#?C5QG?I\N 3<#W<8=T+'/1!8VCJW[J)D&DZHO: M+U7]WKR.]H3>U^M[>QC_9]&@O$6+$!'H0PK5\I^KFWB/ZCE7$)LE%JU,R M9&!D98A* D0TT">"!.@3"CJD%PJ/RSZT4;1G?=[EBE2K>2M/'N^D[ M9S(;![]"V]U&* 3>VHLO]4&?%Y^1B-)OR"\$.46SA#Z)H10$2+ 6BS$L^V W MM2[O(EK!1#@$6:QH7O:XRQS]V;K4F 3-&_B2:41/:][*AC[)*1*7#B(R'.. M>*ULYWC)DU.T#CP]_ PCP#REK[- ;*$5B0]W+"UFQZY8=F4]\:R1.,6HD07Z M'E:$E"X:-)Z$*<0!F"X 0D;WM.QI:&0((1^- 5K)4)7]Z(1*W@1IB8ZN M-_'>I_PA1)YZ'IAS6TL]55I$NS[8="2-PP4PDB_0N;9=BEE4FD@K8-VFL@]] MT/![NO_7#H:2YR:Z%D@FP2+UD/893,CH6A^^G"L] MLV9'L;#$6!C](WU8S??)],U/C<['7(#Z@ <*RK& MI(4&C$G0><>Q #5N6C(1G-DEKD-TWUP.VF.1?.J- :X8GL1$-Q%? 45=U$!T M@(X8[C8S1[+G4X(OFG&259*D"Q$:WUZLFE,2G&HE!!*#_B-"A^V66;.(UM: M6C6$8)+@3G17C",C&LN(%&L5(!L9";D21:B)GY!NP@&EA -BWS0E3T)$! #; M )J$L/F8K-H+CO&%[#JD\$&0GO '$;H[?Z64![6A7%UI23!'%U0QG(G:9P#(+2F;>XIZ+.1_OVS?-MM&X__+E^J'3K"4?-BD@OZ":1M>].9!H^N"N&Z0;%X 7<)V MM2V2_AMF%Y=B:[^XT:QO(*NOQPQ>G<4(($A.\R9OD9C.L\>H!@C<#9TW8O$Z=-8K2K EU6&OG[$DJ<6)!.,E*4INQ7 MI#CFA)_,:>AL,FRWF9(%>M(H&I%E/CK*)JA (;SGJ Y\8[#3^OWN^O%KN]DY M7)+E3Q8'@:'J^P)&QRDG<(IU==8'G25A!%6AT/=3@"@ROI>B+Y,\Q;D8D>9@ M=-S*^M3MG>K<@XV1#;[Z-\IH;Y#]F'-;?WY?<=8[G#DOJ!W S?W%92=V-IUF M\>BS'0%13IW6&;]B;U8DL01;'1Y<2=)%,H,OWJHMLN'[N :_F& [F7-B]$MK MW],Q_V:H0Y_2V",B]H[;+B',T&SB)JV27>HFZ:=A=WV^WP+/5" MROX8W;4?>QB^^CC>)HA^\0XV.'6VIMZZK1-4D 7R43"E2(=B><3V[>]O<1#M MAV*P+;L?AB7Q8-9!F'*?8O7.<3\1Q[6V2R7^8+MH]#GK9>H&T?M$Q$PV\*?, M8Y26Y3&N"M%_NJ+_/Y;Z_P-02P,$% @ SX">7(02#WX32@ _'0% !$ M !D,30V.#8R9&5X.3DQ+FAT;>U]:U/C2++V=R+X#Q7,] 8=IW#K;AEHXC7@ MZ?:);IH%>O;L?A-2&6M'EKRZ0+.__LTL2;YA8P,2MN2:F-TQME27I[(RL_)6 MQU]OOG\[.?[::9^?[.X<]S?7;09^Y=/SZ\",*!Y>V=D-T=>/^, M^3$+3X[/NW_F#S^X3MP_-!NZZ^\1RW/O?&B ]>(]WLUE_MC "N]<_R .AH?2 M,#XBV=^W01P'@_2K7N#'!Y'[7W8HC__N60/7>SQLARZ,@K2_=;]G)YU????6C0G.DQQ_.CTY_G1Y,M'M1)L*M#DSBB>#V#OYFW\;#8^P%9CN MHM'/>0_A@3>ZW[^0ZZNSSWMWLF:8AN)$0TG2&O\>WN'@;S[O??OQY4<*36$# M);C@[=-O'7+6^?;M^K)]UKWX\GE/VN-_7[;/S_.__]$]O_GZ>4^6I ][Y/3' MU7GGBG^?C2']Y@!HXEO[\KISF'^87HIK=_"5N;/+-5H;FY-("@@?V=5)]N$\ M[U]5/\#B?;HY'__R9_9V.L/12)7\P>D&##W_'O[O:J*K?"9#ZXX=W(;,^NO M]2/788?6?> Z9*69G,R,"18!>OOCQ\7-U&)-4N81X=3X1Q 2U[]G41R$44J- M^-K4%&9FFJUCOII/GWM9[P/FN-9LSQRD:8 FICPQXZ^=[I>O0*3F-.KCKPF0 M!! 8#$O96]CV6L"??.*A[\;L(!I:-COT@X?0FFUBW@/_(Z=K8.KF@:+(!ZHJ M:2,0I_]3^F+^#_"R-T_(D%L'NBP=R(HI+Y[(-M#&SY-\4X;,LV(W\*/_%[(( M]DK##@;'GWZ^YS[]>>*SA^?ZSU@:_ =Y^LE\&E8^31KDBI.?_M-UEKS7I-G7IO3P61#T\\B(4W]FH%*II>$+":K9_$% M(KIG?L) -H 3@3T=/M(9/D#B0/RN]S0TK'>NIX'&_"()$-B?B"!3RQBPX:, M+3\F=@([U+#%\18>V($ M)A<,&.F%P8 $0Q:F6L4$[UM*DG)S/D&F+><4B1WL[DST +0I"VH4U#A%C8[K M)3$0'2ABONO?103HA41]*V2HIBTEQ=^51E.;2XQ9PSDU3K:_NS/J -XW#4&2 M@B13DOR10NIZ]^ MX#DL!"G?#X/DKI]1=Z>7 0Q M.R1M\L!N8:8Q3C(]2?WM-U.1FT<1:K8]ABHM RP\CSS -,DM(]:]Y7K6+="1 M%1/M4)7(L#%HD,X-S-NQ'N';;$%_GO3C>'CXZ5-^@FU,'QSQG-B=-7I.S-!X M_02OVQ?DO-OY\H.2]C!TO71$JD33LQZ?HWQ$)L^.^Q?_A,U(KKZ?PSO7_\<_ M?L<>^90UQ#HIT]"/! M RX>;O.AY$,,6<]C=LR/O["60-0)##&*84GOXCXN> #OWGG!+9R#;Y/(]5D4 M4>*$+IR%\/P3^'/E(\=\(\LUYDEN[.^Y8;0(6_OK ,K^-VU_R)_ M6&@ \1JSMN=BT41SP$%PS\*#1_A$87? [#T ) 3H\#P(FS<(8TX(Z8D1=/"' MN$]3I1M/?KL[0T -\%A%>N42*Q=24^<$]FMH 6\.?,JQ4*#[7$U(KP'J8I!1;V#EJ*$ 3D6P/K M+UQOZ!DZ&^)'?+Z7 --#20HRU6-L2/K,\A 0%"Y F/!8_@UVD7ZVL3UH"!OH MP[#*6M5V.GCGWD(NEK-A[#4$F@804EL0(M%+[4&/N3V(KWWZ%+1L)Z@7!]F: M<+JW;!O!B8/='3Z=="-Y "4VA$]@LXY[Y\;0;CIO8*1#Z];UW-AE40I(1E[X M?"\)86A\46#K45R 'KR,G#:ELD:^;S*6\NF\^R?PS\RQQ?T(*$"'J9B?1I$- MGH"(7TWH ;<,=CCH =Z#]1BAI/TTQ$Z^7I'K[K]@3=2]O%WN>#O\K<7_F?', M9,+YK'-QT[EZI>LM\XALH%MH@5-(EU=U"LGSG4*:^>$=[ZMV#7O=[/ MBL\\C^VOV-^ZS_*=.SLTN.<^Y8A[G<[FDSAZ;(\QS'>(9 MEV#!''Z3^#^K^&%O^B%CY#O\U(](!T^>*_N *XZL4BZPT^?WX].K M3$5Y";BO?6*]D]1K-LD/Z5#.^I9_QVHVM[/,Y9Q/ZS9W=W9;W\\_@2OGJ12_<4,9R+2;12[^1LHV7R \),?L5WR U@(_/CS(OUQ!<>GQ8/]TZG!0/UY;MC"N 1MI M-5H"I&WGM;7DK-?,0X\^)7?,9Z'EI:Y[RQFXOLM#*-Q[AJ$!S(]85#ONIYBZ M.,\N!4G3BU4UZPB2/,^6+A JS2SR_)E?J,73:G&N"T. M+$/5S,:FQ#UM+$C*ID@>H46^C=6>+ZQG5Z<\,*RZMR$$NYGP:)MR*MQ8CB?7 MGN/5DK^]4)5\I@IGQA4KJEJ6RCW,REO=2H5'%;:,91B5'$>Z1N:Z.^]ZB0G& M)N+ZH*B:I"HJK0PDF*JD*S+XFJ0J*J4 %F="J; M-8AY*Q$AE39;I@AX>U^;4BTST$55(5%5:''[ABPJ72QM7S<%2,M!VA!9)?R9 MHJK09NX00RFVD&8]V4A+@"1X;2TYZW97%3(5583.+6N_J>@B%7GIH5^81=8< M:B/48E%5J&QQ(3>K7W9>B(L- $F(BV7MBZI"HJK0RRA&:2HB47@I2)I(.5_. MG3&\'"9%E02C7@K3IL3@"Z.SJ"VT85N# M8G4AH<@L9[2F(>P52V':%%$D(BE$?:&%6UE6"[[^IY9;F4J*+#3PI3!MBE]8 MJ):BR- &; >J2*JHH+,"KD=A0::C::E5JDZ+0T"N"JAK*INR-382G"<1:=7B$.OEJYKI;6J&AK*W5"@9E MX,RPZ\GZ0[-UBF;K&$W6+HQ\)HN$QD@>9"]K'_:F1$-.*,CJ]TYX M%8(WYUF\ O#)] V0&/#YA#"?ME>XF#O\=]1N!4P>R8 M!#ULCH&XV-VQLU(8I.@ MDV'((BP>XC3()$X@]>S$LV+&L7C2^V03?$9Q:/D1?QYZS*<>(UQNX"SH.HER M\#+(QLT#MKRB"@FAR0B>L6+H)60XO0QI)PGSUV$.]VZ01##.P= *K5N@X[3G M!OD:/#"0XW3.' ;,BA*8/B@#0>(YQ ]BC$+_30\&Z#ZV;AN$"?P/"O8.3!C?OI8% %:I"16L)9UXAQU9CEG&X,R[EF?", M 0 UV:[G9B34(TMU6'\F2V .0<"Z8^,Q)W0@,\Y_@#*"WNY.MA^B"/KVX 6V MD!#&($Q@()L32ON+, Y>7H"&O6Y&]D)L-)TNC=]-W3(WQ,KA#U#KEB4>'%$ M4JWYE&O.L%CS!B*]81S=D[;G9

XL7W MWX,;,60$L+MRU5Z(^CWYPSS]*OM1>793_NTW66O->TV>>6U.!\_OX*E?7[R= MG\4WKZA$[D+V0&X?B9D.#@@&*VVEDOFI0,EDL1."9/#Q-=>W0]R#&/,]0-Z- MJ@8*U&$0QKW

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end XML 17 d146862d8k_htm.xml IDEA: XBRL DOCUMENT 0000943819 2026-04-30 2026-04-30 RESMED INC US false 0000943819 8-K 2026-04-30 DE 001-15317 98-0152841 9001 Spectrum Center Blvd. San Diego CA 92123 (858) 836-5000 false false false false Common Stock, $0.004 par value RMD NYSE false